Company / Depreciation & Amortization
Gain Therapeutics, Inc. Depreciation & Amortization History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$83.6K
FY2024
5-year range
$9.6K / $83.6K
FY2021-FY2024
Trend
+30.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has increased for 3 consecutive years, from $9,592 in FY2021 to $83,579 in FY2024.
Based on SEC 10-K filings.
$83,579 in FY2024 with a 3-year CAGR of +105.8%.
Increased from $15,484 to $83,579 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +105.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 3-year CAGR of +105.8%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 30.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $83.6K | +30.3% |
| FY2023 | $64.2K | +314.4% |
| FY2022 | $15.5K | +61.4% |
| FY2021 | $9.6K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026